Aggressive recurrent respiratory papillomatosis: A series of five consecutive patients successfully treated with adjuvant intravenous bevacizumab. A single Belgian academic center experience.

Recurrent respiratory papillomatosis (RRP) is a currently incurable benign neoplasm caused by human papilloma virus (HPV) infection. It usually reduces voice, respiratory, and general quality of life, and is sometimes life-threatening. Patients usually need repeated operations. The use of adjuvant bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor A, has been described in several case reports, with a good efficacy and safety profile. We report the cases of five patients with aggressive RRP who were treated with adjuvant systemic bevacizumab in a single Belgian tert... Mehr ...

Verfasser: Collette, Fanny
Lawson, Georges
Hassid, Samantha
Delahaut, Gilles
Bachy, Vincent
Van der Vorst, Sébastien
Faugeras, Laurence
Gilliaux, Quentin
D'Hondt, Lionel
Dokumenttyp: Artikel
Erscheinungsdatum: 2023
Schlagwörter: benign neoplasm / bevacizumab / human papilloma virus / laryngeal tumor / recurrent respiratory papillomatosis
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-26495840
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : http://hdl.handle.net/2078.1/273289